Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Brain/Neuro Cancer: Recurrent GlioblastomaNCT ID: NCT02017717
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-630
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center
Overall PI: David Reardon, MD,
Dana Farber Cancer Institute
Site-responsible Investigators: Jorg Dietrich, M.D.,
Massachusetts General HospitalEric Wong, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060